Quantcast

Latest Management of cancer Stories

2014-06-24 08:31:08

U.S. Phase 2a Clinical Trial in Recurrent Glioblastoma to Initiate in Early 2015 SYDNEY, June 24, 2014 /PRNewswire/ -- EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV(TM) nanocells packaged with doxorubicin for the treatment...

2014-06-24 08:30:24

Using CyberKnife and chemotherapy, doctors treat primary and metastatic tumors FENTON, Mo., June 24, 2014 /PRNewswire/ -- When St. Louis CyberKnife patient Theresa Thompson was diagnosed with stage IV lung cancer, doctors determined the disease had spread beyond her lungs to her brain. http://photos.prnewswire.com/prnvar/20140623/120686 While stage IV lung cancer is difficult to treat, doctors reviewed her case and decided to aggressively treat with CyberKnife and chemotherapy....

2014-06-24 08:29:35

Yet Canadians in the dark about cancer survival rates OTTAWA, June 24, 2014 /CNW/ - Cancer isn't always a matter of life and death anymore - today, an increasing number of Canadians are living with cancer as a chronic condition. However, the majority of Canadians and the healthcare system have not necessarily responded to this shift. "The fact is, 63 per cent of Canadian cancer patients live longer than five years after diagnosis(i), and if a cancer patient survives past one year,...

2014-06-18 04:21:16

Unique Immuno-Oncolytic Therapy Gets Closer to a More Effective, Safer Cancer Treatment and Potential Cure CLEVELAND, June 18, 2014 /PRNewswire-USNewswire/ --­­ Western Oncolytics Ltd., a biotech company specializing in immuno-oncolytic cancer therapies, has closed $275,000 in seed funding. The proceeds are planned to set a path toward clinical trials and execute initial manufacturing for its novel virus-based cancer therapy, which delivers genes to guide the immune system to kill...

2014-06-17 08:29:05

Side-By-Side Genomic Analysis of Patients' Tumor and TumorGraft Mouse Avatars Before and After Treatment Also to be Conducted NEW YORK and HACKENSACK, N.J., June 17, 2014 /PRNewswire/ -- Icahn School of Medicine at Mount Sinai and Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the initiation of a clinical trial evaluating the use of Champions...

2014-06-16 08:28:29

Company continues to engage leading cancer treatment centers to investigate non-invasive methods of cancer mutation detection in order to advance patient care SAN DIEGO, June 16, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time...

2014-06-12 23:14:11

Beneufit’s cFIT™ system allows physicians to prescribe exercise and quantify the impact of specifically followed exercise programs to quality of life in cancer survivors. San Francisco, CA (PRWEB) June 12, 2014 Beneufit’s cFIT™ was selected as a semifinalist to move on to the second phase of the LIVESTRONG Foundation’s inaugural Big C competition, aiming to change the way the world lives with cancer. cFIT, that applies data-driven exercise protocols to help patients manage...

2014-06-10 16:26:49

SCHAUMBURG, Ill., June 10, 2014 /PRNewswire-USNewswire/ -- Extensive clinical experience suggests that hyperthermic intraperitoneal chemotherapy (HIPEC) may play an important role in the ongoing treatment of colorectal cancer patients with peritoneal carcinomatosis (CRCPC). However, there is no established nonsurgical process to select patients for HIPEC treatment as part of recommended standard of care or for clinical trial inclusion....

2014-06-10 08:29:31

Successful collaboration with AstraZeneca includes two novel cancer drugs in clinical development CARLSBAD, Calif., June 10, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that AstraZeneca has initiated a Phase 1 clinical study of ISIS-AR(Rx) in patients with cancer. Isis earned a $15 million milestone payment associated with the clinical advancement of ISIS-AR(Rx). ISIS-AR(Rx) is an antisense drug designed to treat patients with prostate cancer by...

2014-06-04 11:26:06

American Heart Association Study Highlights: -About 12 percent of older breast cancer patients developed heart failure within three years, often as a result of the cancer drugs and treatments. -Only a third of older breast cancer patients saw a cardiologist within 90 days of developing heart problems. -Those who saw a cardiologist were more likely to receive standard drugs for heart failure than those who didn’t. Only a third of older breast cancer patients saw a cardiologist...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related